Sanofi India
Sanofi India provides medicines for the treatment of patients in several therapeutic areas: cardiology, thrombosis, oncology, diabetes, central nervous system, internal medicine and consumer healthcare. The French parent company, Sanofi and Hoechst together hold 60.4% of the share capital.
The company posted a good, consistent set of performance for Q2CY16 (the company has a 31st Dec year ending). On a 11% (YoY) rise in total income at Rs.608 crore, the company’s net profit rose 33% at Rs.85 crore. EBITDA for the quarter was up 20% at Rs.146 crore while margins jumped up from 22.1% to 24%.
For H1CY16, the company’s net profit rose 29% at Rs.166 crore. Typical of MNCs, it’s a debt free company and reserves stands at a healthy Rs.1600 crore. Equity is at Rs.28 crore. Annualized EPS stands at Rs.144 (FV Rs.10/share).